X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Signifor (Pasireotide) – Treatment for Cushing’s Disease, Germany

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Europe, Projects

Signifor (SOM230 / Pasireotide) is a somatostatin analogue indicated for the treatment of patients with Cushing’s disease for whom surgery has failed. The drug is developed and manufactured by Novartis.

In April 2012, Signifor was approved by the European Commission (EC) for treating adult patients with Cushing’s disease.

About Cushing’s Disease

 

“Signifor is a somatostatin analogue indicated for the treatment of patients with Cushing’s disease for whom surgery has failed.”

Cushing disease is an endocrine disorder caused by a tumour on the pituitary gland. It is a serious condition where the pituitary gland releases excessive adrenocorticotropic hormone (ACTH). It occurs due to excessive urinary-free cortisol (UFC) levels in the body, and affects adults aged between 20 and 50 years. Women are three times more likely to be affected than men.

The disease is estimated to affect about 10 to 15 of every million people each year.

Signifor’s mechanism of action

 

Signifor contains a somatostatin analogue. The drug works by activating somatostatin receptors in the pituitary adenoma, which results in inhibiting the excessive ACTH and lowering urinary-free cortisol (UFC) levels. The drug is available as a 0.6mg injection.

Signifor clinical trial phases I and II

 

Novartis conducted phase I clinical trials on Signifor between July 2008 and April 2009. It was an open label, interventional and single-group assignment which evaluated the safety and efficacy of Signifor. The study enrolled 34 patients. The primary outcome measure was determining the pharmacokinetic profile of a Signifor single dose injection. The secondary outcome measure was determining safety after a single Signifor injection.

“The drug works by activating somatostatin receptors in the pituitary adenoma, which results in inhibiting the excessive ACTH and lowering urinary-free cortisol levels.”

Novartis conducted phase II clinical trials on Signifor in an open label, interventional and single-group assignment that enrolled 26 patients with Cushing’s disease. The primary outcome measure was finding UFC after 15 days of treatment. The secondary outcome measures included safety, tolerability, ACTH, serum cortisol and pharmacokinetics.

Phase III clinical trials on Signifor/Pasireotide

 

The EU approval for Signifor was based on phase III clinical trial known as Pasport-Cushings. It was a prospective, randomised, double-blind study, conducted in 68 sites across 18 countries. The 12-month study evaluated the efficacy and safety of Signifor in 162 patients who were administered with a 900µg and 600µg injection twice a day.

Related Project

Tesofensine Anti-Obesity Medication

Under development by NeuroSearch, a Danish pharmaceutical company, tesofensine is a novel treatment for obesity.

The study’s results, announced in March 2012, showed that Signifor 900µg and 600µg drug doses normalised the mean UFC levels in the body by 26.3% and 14.6% respectively. The patients met the primary endpoint, normalisation of UFC, after six months. The study also demonstrated that the median reduction of mean UFC was 47.9% in both dose groups of the drug. The results further showed that Signifor reduced the manifestations of Cushing’s disease, which included the blood pressure, total cholesterol, as well as weight and body mass index in twelve months. The most commonly reported adverse events for Signifor included nausea, hyperglycemia, diarrhea, diabetes mellitus, injection site reactions, abdominal pain and fatigue.

Novartis initiated another phase III clinical trial on Signifor in November 2011. It is a randomised, double-blind, multicenter, phase III study which evaluates the efficacy and safety of Signifor in two dosing regimens of long acting release (LAR). The study enrolled 148 patients.

The primary outcome measure of the study will include finding the proportion of responders in each of the two Signifor LAR regimens. The secondary outcome measure will include finding change in mean UFC from the base line and change in controlled mUFC. The results of the study are expected by January 2016.

Marketing commentary

 

Signifor is the only pituitary-targeting medicine available on the market for Cushing’s disease. The drug is expected to capture a $90.8m market by 2019. A medication approved for the same indication is Korlym (mifepristone) which was developed by Corcept Therapeutics.

Tags: Europe
Previous Post

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Next Post

Bidachem Active Pharmaceutical Ingredients Plant, Bergamo, Italy

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Gilead's drug remdesivir gets US FDA's emergency use authorisation for COVID-19
Europe

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

4th May 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Bidachem Active Pharmaceutical Ingredients Plant, Bergamo, Italy

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In